Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?
As evidenced by the recent approvals of Removab (EU, Trion Pharma) in 2009 and of Blincyto (US, Amgen) in 2014, the high potential of bispecific antibodies in the field of immuno-oncology is eliciting a renewed interest from pharmaceutical companies. Supported by rapid advances in antibody engineeri...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2015-12-01
|
| Series: | Antibodies |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2073-4468/5/1/1 |